Florida Cancer Specialists & Research Institute Presents Groundbreaking Cancer Research at 2025 ASCO Annual Meeting

Strategic Insights -

Floridan physicians and researchers have made significant contributions to the field of cancer care, presenting cutting-edge studies at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The meeting, which brings together oncology professionals from around the world, features research conducted at Florida Cancer Specialists & Research Institute (FCS), a leading private oncology practice in Florida.

Key findings from the studies presented by FCS researchers highlight advances in precision oncology, including the development of new treatments for various types of cancer. The research, which spanned new approaches and cutting-edge targeted therapies, was made possible through partnerships with other leading clinical research organizations and technology platforms.

Key Takeaways:

  • Thirteen physicians and researchers from FCS presented 34 clinical research studies, highlighting the institute's commitment to advancing cancer care through research.
  • The studies focused on various areas, including precision oncology, targeted therapies, and immunotherapy, with many studies presenting preliminary results or updates on ongoing phase 1, 2, and 3 trials.
  • Research conducted at FCS has resulted in several groundbreaking discoveries, including the development of new treatments for rare and advanced forms of cancer.
  • The research presented at ASCO 2025 highlights FCS's position as a leader in clinical research among private oncology practices in Florida and nationwide.
  • Many of the studies presented were made possible through partnerships between FCS and other leading clinical research organizations and technology platforms.
  • FCS's robust research program is a cornerstone of its mission to deliver world-class cancer care to patients.

Statistics:

  • 34: The number of clinical research studies presented by FCS researchers at ASCO 2025.
  • 13: The number of FCS physicians and researchers who presented studies at ASCO 2025.
  • 5: The number of
  • 3: The number of phase 2 studies presented by Manish R. Patel, MD, on new approaches and cutting-edge targeted therapies.
  • 34: The number of abstracts featuring FCS research presented at ASCO 2025, including multiple study names such as CUSP06, ZL-1310, BG-C9074, utidelone capsule, SIRPï monoclonal antibody, BI 770371, E7386, RIB, NSAI, LODiSTAR, and TIGOS-LS.

Sources:

  • 1: Florida Cancer Specialists & Research Institute (FCS) website
  • 2: The American Society of Clinical Oncology (ASCO) press release
  • 3: ASCO Annual Meeting Program and Abstracts (2025)
  • 4: Florida Cancer Specialists & Research Institute (FCS) presentation at ASCO 2025